Astra Zeneca and Merck partner on drug regimen

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Roman Fabbricatore

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Cristiane Decat Bergerot, PhD

April 14th 2025

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Zeynep Ozlem Soran;Allison Brophy;Lily Kass;Berkay Demirors;Hayeon Kim;Atilla Soran, MD, MPH;John Austin Vargo;Parul Barry

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

Related Content

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Roman Fabbricatore

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Cristiane Decat Bergerot, PhD

April 14th 2025

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Zeynep Ozlem Soran;Allison Brophy;Lily Kass;Berkay Demirors;Hayeon Kim;Atilla Soran, MD, MPH;John Austin Vargo;Parul Barry

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC